Perseus Proteomics, Inc. (JP:4882)
:4882
Want to see JP:4882 full AI Analyst Report?
4882 Stock Chart & Stats
¥220.00
-¥14.00(-2.34%)
At close: 4:00 PM EST
¥220.00
-¥14.00(-2.34%)
Day’s Range― - ―
52-Week Range¥176.00 - ¥478.00
Previous CloseN/A
Volume686.20K
Average Volume (3M)226.58K
Market Cap
¥3.06B
Enterprise Value¥1.42B
Total Cash (Recent Filing)¥1.51B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-58.44
Shares Outstanding16,999,600
10 Day Avg. Volume184,610
30 Day Avg. Volume226,583
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.69
Price to Sales (P/S)24.20
P/FCF Ratio-4.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-62.5
Revenue Forecast (FY)¥120.00M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsistent revenue expansion from 67.9M in 2021 to 135.5M in 2026 demonstrates enduring customer demand and market traction. Sustained top-line growth provides scale to absorb fixed costs, supports future margin improvement, and underpins long-term operational viability if leveraged correctly.
Debt-free Balance SheetA no-debt capital structure and substantial assets reduce solvency risk and provide strategic optionality. Lower financial leverage preserves flexibility to access capital or finance investments while navigating ongoing losses, improving resilience over the medium term.
Strong Gross ProfitabilityConsistently high gross profitability indicates structural product-level margins or efficient COGS, offering a durable foundation. These margins create a pathway to long-term operating profitability as scale increases and SG&A is optimized, enhancing sustainable cash conversion potential.
Bears Say
Persistent Operating LossesChronic operating and net losses undermine earnings power and absorb capital, preventing self-sustaining growth. Unless operating profitability improves, losses will continue to erode returns, constrain reinvestment capacity, and force reliance on external funding over the medium term.
Ongoing Cash BurnSustained negative operating and free cash flow, even with modest improvement, signals continued dependence on external financing. Persistent cash burn raises dilution and liquidity risk, limiting ability to fund R&D, commercialization, or expansion without material capital raises.
Erosion Of Shareholders' EquitySignificant equity decline over several years reflects cumulative losses and weak returns to shareholders. A diminished capital base reduces the buffer against shocks, limits strategic flexibility for investments or M&A, and increases vulnerability to adverse funding conditions.
Perseus Proteomics, Inc. News
4882 FAQ
What was Perseus Proteomics, Inc.’s price range in the past 12 months?
Perseus Proteomics, Inc. lowest stock price was ¥176.00 and its highest was ¥478.00 in the past 12 months.
What is Perseus Proteomics, Inc.’s market cap?
Perseus Proteomics, Inc.’s market cap is ¥3.06B.
When is Perseus Proteomics, Inc.’s upcoming earnings report date?
Perseus Proteomics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 94 days.
How were Perseus Proteomics, Inc.’s earnings last quarter?
Perseus Proteomics, Inc. released its earnings results on May 14, 2026. The company reported -¥11.03 earnings per share for the quarter, missing the consensus estimate of N/A by -¥11.03.
Is Perseus Proteomics, Inc. overvalued?
According to Wall Street analysts Perseus Proteomics, Inc.’s price is currently Overvalued.
Does Perseus Proteomics, Inc. pay dividends?
Perseus Proteomics, Inc. does not currently pay dividends.
What is Perseus Proteomics, Inc.’s EPS estimate?
Perseus Proteomics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Perseus Proteomics, Inc. have?
Perseus Proteomics, Inc. has 16,999,600 shares outstanding.
What happened to Perseus Proteomics, Inc.’s price movement after its last earnings report?
Perseus Proteomics, Inc. reported an EPS of -¥11.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.047%.
Which hedge fund is a major shareholder of Perseus Proteomics, Inc.?
Currently, no hedge funds are holding shares in JP:4882
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Perseus Proteomics, Inc.
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Technical Analysis
Trans Genic Inc.
―
Cosmo Bio Co., Ltd.
―
ReproCELL Inc.
―
Human Metabolome Technologies, Inc.
―
Precision System Science Co.,Ltd
―
Options Prices
Currently, No data available
---